161 related articles for article (PubMed ID: 38030594)
1. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
[TBL] [Abstract][Full Text] [Related]
2. CD24 induced cellular quiescence-like state and chemoresistance in ovarian cancer cells via miR-130a/301a-dependent CDK19 downregulation.
Jang Y; Kang S; Han HH; Kim BG; Cho NH
Cell Death Discov; 2024 Feb; 10(1):81. PubMed ID: 38360723
[TBL] [Abstract][Full Text] [Related]
3. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
4. The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
[TBL] [Abstract][Full Text] [Related]
5. CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.
Burgos-Ojeda D; Wu R; McLean K; Chen YC; Talpaz M; Yoon E; Cho KR; Buckanovich RJ
Mol Cancer Ther; 2015 Jul; 14(7):1717-27. PubMed ID: 25969154
[TBL] [Abstract][Full Text] [Related]
6. CD44
Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
8. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
[TBL] [Abstract][Full Text] [Related]
9. The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma.
Tsai SC; Lin CC; Shih TC; Tseng RJ; Yu MC; Lin YJ; Hsieh SY
Mol Carcinog; 2017 Sep; 56(9):2035-2047. PubMed ID: 28383782
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis.
Zhang XY; Zhu BC; He M; Dong SS
J Ovarian Res; 2024 May; 17(1):102. PubMed ID: 38745302
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
14. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
15. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
16. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
17. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
18. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
19. Ascitic fluid shear stress in concert with hepatocyte growth factor drive stemness and chemoresistance of ovarian cancer cells via the c-Met-PI3K/Akt-miR-199a-3p signaling pathway.
Hassan AA; Artemenko M; Tang MKS; Shi Z; Chen LY; Lai HC; Yang Z; Shum HC; Wong AST
Cell Death Dis; 2022 Jun; 13(6):537. PubMed ID: 35676254
[TBL] [Abstract][Full Text] [Related]
20. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
